Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
02:02pm, Friday, 20'th May 2022 Benzinga
Upgrades
For Telia Company AB (OTC:TLSNY), UBS upgraded the previous rating of Neutral to Buy. For the first quarter, Telia Company had an EPS of $0.05, compared to year-ago quarter EPS of $0.03. The
Where Spero Therapeutics Stands With Analysts
01:15pm, Tuesday, 17'th May 2022 Benzinga
Within the last quarter, Spero Therapeutics (NASDAQ:SPRO) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
0
L
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2022 Results - Earnings Call Transcript
09:42pm, Monday, 16'th May 2022
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations Ankit Mahadevia - Chief Executive
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates
09:35pm, Monday, 16'th May 2022 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates
06:48pm, Monday, 16'th May 2022
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
12:35pm, Thursday, 12'th May 2022 Zacks Investment Research
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -11.90% and 4.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics to Present at Upcoming Investor Conferences
12:05pm, Wednesday, 11'th May 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commerciali
Spero Therapeutics to Present at Upcoming Investor Conferences
08:05am, Wednesday, 11'th May 2022
CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022
12:05pm, Monday, 09'th May 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022
08:05am, Monday, 09'th May 2022
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022
02:17pm, Wednesday, 04'th May 2022 Benzinga
Upgrades
Craig-Hallum upgraded the previous rating for Pros Holdings Inc (NYSE:PRO) from Hold to Buy. Pros Holdings earned $0.21 in the first quarter, compared to $0.22 in the year-ago quarter. At the
Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates
01:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
SPRO Stock Alert: 9 Things to Know as Spero Therapeutics Plunges 50%
11:23am, Tuesday, 03'rd May 2022
Spero Therapeutics (SPRO) stock is taking a beating on Tuesday after the biotech company revealed a change in strategic direction. The post SPRO Stock Alert: 9 Things to Know as Spero Therapeutics Plu
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline
11:05am, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advancement of SPR720 and SPR206
